B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.
B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.